Will the results be positive?
The market price is nearly balanced between yes and no outcomes. Given the intrinsic forecast of a 45% chance of a positive outcome and the current market prices, there is no strong incentive to buy or sell. The...
The intrinsic probability (65%) is higher than the market price of 49.88%, indicating the asset is undervalued. However, given the uncertainty inherent in Phase 2 trials and the current portfolio constraints, a BUY...
Intrinsic probability (48%) is very close to market price (49.9%). The gap is too small to justify a trade given the high uncertainty and the demanding endpoints. No meaningful edge exists.
Merck discontinued favezelimab entirely in 2024. Published trial data in 2025 confirmed the combo failed to improve efficacy over pembrolizumab alone (59% vs 64% benefit rate) but added toxicity. A clear NO.
Intrinsic 42% < yesPrice 50%, NO undervalued ~8%. Moderate edge/confidence justifies max buy NO within cap; no position held.
